Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.

Literature DB >> 9257776

Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.

P Belanger¹, C C Nast, R Fratti, H Sanati, M Ghannoum.

Abstract

The effects of voriconazole on the growth, ultrastructure, and leakage of cytoplasmic materials of Candida species were investigated. MIC data showed that voriconazole was more active than fluconazole. Exposure of yeast to voriconazole caused growth inhibition, cell wall thinning, and cell membrane degradation. Neither cell collapse nor release of cytoplasmic materials was observed in the treated cells.

Entities: Chemical Species

Mesh：

Substances：

Year: 1997 PMID： 9257776 PMCID： PMC164020

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

2 in total

1. Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata.

Authors: M A Ghannoum
Journal: Mycopathologia Date: 1986-09 Impact factor: 2.574

2. Antimycotic effects of octenidine and pirtenidine.

Authors: M A Ghannoum; K A Elteen; M Ellabib; P A Whittaker
Journal: J Antimicrob Chemother Date: 1990-02 Impact factor: 5.790

2 in total

19 in total

Review 1. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors: M A Ghannoum; L B Rice
Journal: Clin Microbiol Rev Date: 1999-10 Impact factor: 26.132

Review 2. Fungal resistance.

Authors: H Bernhardt; K Zimmermann; M Knoke
Journal: Infection Date: 1999 Impact factor: 3.553

3. Serum voriconazole levels following administration via percutaneous jejunostomy tube.

Authors: Valérie Martinez; Jean-Luc Le Guillou; Christian Lamer; Melissande Le Jouan; Michel Tod; Françoise Dromer
Journal: Antimicrob Agents Chemother Date: 2003-10 Impact factor: 5.191

4. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

Authors: M A Pfaller; J Zhang; S A Messer; M E Brandt; R A Hajjeh; C J Jessup; M Tumberland; E K Mbidde; M A Ghannoum
Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191

5. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors: J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191

6. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors: S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal: Antimicrob Agents Chemother Date: 2000-05 Impact factor: 5.191

Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.

1. Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata.

2. Antimycotic effects of octenidine and pirtenidine.

Review 1. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Review 2. Fungal resistance.

3. Serum voriconazole levels following administration via percutaneous jejunostomy tube.

4. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.

5. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

6. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

7. Evaluation of voriconazole pharmacodynamics using time-kill methodology.

8. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.

9. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

10. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.